Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
01 July 2015Website:
http://www.natera.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:26:47 GMTDividend
Analysts recommendations
Institutional Ownership
NTRA Latest News
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the International Society of Prenatal Diagnosis (ISPD), the conference will take place July 7-10, 2024, in Boston, MA. Below is the list of poster presentations that will be shared at the.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera's ability to detect rejection in heart transplant patients. Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by.
The Investment Committee gives you their top stocks to watch for the second half.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera donor-derived cfDNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 taking place June 1–5, 2024. Natera and its collaborators will present 18 abstracts highlighting new Prospera data across heart, lung, kidney, and multi-organ transplantation. This includes an oral presentation highlightin.
The global market size for personalized medicines is estimated to reach $1,233.23 billion by 2033, with North America experiencing significant growth in the oncology sector. Natera Inc., a diagnostic company, focuses on women's health, oncology, and organ health, with major revenue drivers including non-invasive prenatal tests and personalized molecular residual disease tests. Natera reported a 43% year-on-year increase in revenue in Q4 2023, with a goal to achieve cash flow break even by Q3 2024 or sooner.
Does Natera (NTRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Natera is a leading company in the field of molecular diagnostics, capitalizing on the growing potential and widespread application in modern healthcare. The company has a proven track record and established trust in the technology, offering investors an opportunity to monetize population cancer screening and diagnostics. Natera stands at the forefront of the transformative shift in non-invasive prenatal screening and has the potential to tap into its growing potential.
Today, we circle back on Natera, Inc., a fast-growing diagnostic testing concern. The company continues to rack up impressive sales growth, but its cash burn remains a primary concern. With Natera, Inc. stock down some 30% from recent highs, is now the time to buy the dip? An updated analysis follows in the paragraphs below.
What type of business is Natera?
Natera, Inc. is a diagnostic company that provides services in the field of reproductive health and genetic disease diagnostics. The company was founded in 2004 and is located in San Carlos, California. The company's main product is Panorama, a non-invasive prenatal test (NIPT) that detects fetal chromosomal abnormalities, including Down syndrome, Edwards syndrome, Patau syndrome, Turner syndrome, and triploidy. It also detects pathologies that often lead to intellectual disabilities, severe organ anomalies, and miscarriage. Panorama can also determine the sex of the fetus in a singleton pregnancy, as well as each fetus in a twin pregnancy. Panorama is also the only commercially available NIPT that can determine whether a set of twins is identical, monozygotic, dizygotic, or trizygotic.
What sector is Natera in?
Natera is in the Healthcare sector
What industry is Natera in?
Natera is in the Diagnostics & Research industry
What country is Natera from?
Natera is headquartered in United States
When did Natera go public?
Natera initial public offering (IPO) was on 01 July 2015
What is Natera website?
https://www.natera.com
Is Natera in the S&P 500?
No, Natera is not included in the S&P 500 index
Is Natera in the NASDAQ 100?
No, Natera is not included in the NASDAQ 100 index
Is Natera in the Dow Jones?
No, Natera is not included in the Dow Jones index
When does Natera report earnings?
The next expected earnings date for Natera is 02 August 2024